Treatment Protocol of Velaglucerase Alfa for Patients With Type 1 Gaucher Disease
Multicenter Open-Label Treatment Protocol to Observe the Safety of Gene-Activated™ Human Glucocerebrosidase (GA-GCB, Velaglucerase Alfa) ERT in Newly Diagnosed or Previously Treated (With Imiglucerase) Patients With Type 1 Gaucher Disease
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Expanded Access Type
Expanded Access Type
- Individual Patients: Allows a single patient, with a serious disease or condition who cannot participate in a clinical trial, access to a drug or biological product that has not been approved by the FDA. This category also includes access in an emergency situation.
- Intermediate-size Population: Allows more than one patient (but generally fewer patients than through a Treatment IND/Protocol) access to a drug or biological product that has not been approved by the FDA. This type of expanded access is used when multiple patients with the same disease or condition seek access to a specific drug or biological product that has not been approved by the FDA.
- Treatment IND/Protocol: Allows a large, widespread population access to a drug or biological product that has not been approved by the FDA. This type of expanded access can only be provided if the product is already being developed for marketing for the same use as the expanded access use.
- Intermediate-size Population
Contacts and Locations
Study Locations
-
-
Arizona
-
Phoenix, Arizona, United States, 85013
- St Joseph's Hospital & Medical Center
-
-
California
-
Beverly Hills, California, United States, 90211-1850
- Tower Hematology Oncology
-
La Jolla, California, United States, 92093
- Rady's Children's Hospital of San Diego
-
Los Angeles, California, United States, 90027
- Southern California Permanente Medical Group
-
Sacramento, California, United States, 95815
- The Permanente Medical Group
-
Stanford, California, United States, 94305-5208
- Stanford University Medical Genetics
-
-
Colorado
-
Denver, Colorado, United States, 80218
- Rocky Mountain Cancer Centers
-
-
Connecticut
-
New Haven, Connecticut, United States, 06510
- Yale University
-
-
Florida
-
Coral Springs, Florida, United States, 33065
- University Research Foundation for Lysosomal Storage Diseases
-
Gainesville, Florida, United States, 32605-4218
- Gainesville Hematology Oncology Associates
-
Orlando, Florida, United States, 32804-4603
- Adventis Healthcare System dba Florida Hospital
-
Palm Harbor, Florida, United States, 34685
- East Lake Oncology
-
-
Georgia
-
Decatur, Georgia, United States, 30033
- Emory Genetics
-
-
Illinois
-
Chicago, Illinois, United States, 60614
- Children's Memorial Hospital
-
-
Iowa
-
Iowa City, Iowa, United States, 52242
- University of Iowa Hospitals and Clinics
-
-
Maryland
-
Annapolis, Maryland, United States, 21401
- Annapolis Oncology Center
-
Baltimore, Maryland, United States, 21215
- Sinai Hospital of Baltimore
-
-
Massachusetts
-
Shrewsbury, Massachusetts, United States, 01545
- University of Massachusetts
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55404
- Children's Hospitals and Clinics of Minnesota
-
-
Missouri
-
Kansas City, Missouri, United States, 64108-4619
- The University Research Foundation for Lysosomal Storage Diseases
-
-
New Jersey
-
Paterson, New Jersey, United States, 07503
- St. Joseph's
-
-
New York
-
Buffalo, New York, United States, 14215
- Hemophilia Center of Western New York Incorporated
-
Manhasset, New York, United States, 11030
- North Shore Hematology/Oncology - Manhasset
-
New York, New York, United States, 10016
- New York University School of Medicine
-
New York, New York, United States, 10029-6500
- Mount Sinai School of Medicine
-
-
North Carolina
-
Asheville, North Carolina, United States, 28801-4420
- Fullerton Genetic
-
Durham, North Carolina, United States, 27710
- Duke Medical Center
-
-
Ohio
-
Akron, Ohio, United States, 44308
- Akron Children's Hospital
-
Cincinnati, Ohio, United States, 45229
- Cincinnati Children's Hospital Medical Center
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Children's Hospital of Philadelphia
-
-
Virginia
-
Charlottesville, Virginia, United States, 22908-0386
- University of Virginia Health Systems
-
Springfield, Virginia, United States, 22152
- O & O Alpan, LLC
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- The patient has a documented diagnosis of type 1 Gaucher disease
- The patient is > 2 years of age
- The patient has NOT previously experienced an anaphylactic or anaphylactoid reaction to another ERT including imiglucerase
- Women of child-bearing potential must agree to use a medically acceptable method of contraception at all times during the study; and must have a negative result to a pregnancy test as required throughout their participation in the study. Male patients must use a medically acceptable method of birth control throughout their participation in the study and must report their partner's pregnancy.
- The patient is sufficiently cooperative to participate in this treatment plan as judged by the Investigator
If the patient is naïve or new to treatment, the patient has one or more of the following (in absence of the following criteria, please call the sponsor for treatment justification):
- Gaucher disease-related anemia
- Moderate splenomegaly (2 to 3 cm below the left costal margin), by palpation
- Gaucher disease-related thrombocytopenia
- Gaucher disease-related palpable enlarged liver
Exclusion Criteria: None
Study Plan
How is the study designed?
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Metabolic Diseases
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Genetic Diseases, Inborn
- Metabolism, Inborn Errors
- Lysosomal Storage Diseases
- Lipid Metabolism Disorders
- Brain Diseases, Metabolic
- Brain Diseases, Metabolic, Inborn
- Sphingolipidoses
- Lysosomal Storage Diseases, Nervous System
- Lipidoses
- Lipid Metabolism, Inborn Errors
- Gaucher Disease
Other Study ID Numbers
Other Study ID Numbers
- HGT-GCB-058
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.